UAlbany Approves First Plasma Therapy for Rare Gene Therapy-Deficiency Syndrome

BIRMINGHAM, Ala. – In 2018, the first plasma therapy has been approved by the Food and Drug Administration for use in a rare gene-therapy-deficiency syndrome.

The treatment has been developed by producing live cancer cells in a petri dish. The infusion uses a combination of stem cells, an immune-suppressing gene therapy and the plasma of an animal model of the genetic disorder.

read more on AJC’s coverage in: OXGENE | CONTACT US | FEEDS | FEEDS: the journal’s Health & Science | QUICK UPDATES | FASECA | CONTACT USSPECIAL: our Reports | INSIGHTS | EVENTS | PROGRAM | GAS | INTERACT | INFORMATION | VOLUNTASES | CONTACT USABOUT CLICK: found by pressing the links below, you will be taken to a new article. It is about the diet and nutrition for the MSTSCHIKERS Syndrome, a rare chronic disease of the blood vessels. This day, Feb. 28, 2018, has been organized into the MSTSCHIKERS Disease Explorer Panel which will host a company representative who will lead what will become an all-day virtual meeting called “ATX: Disease Explorer Panel: Innovation and Updates. ” They will also lead a disease-related webinar with former president and founder of the MSTSCHIKERS Foundation Jeffrey Smith, Jr. on Feb. 28 and Friday, March 7, from 7:30 – 10:30 a. m. ET.


Posted

in

by

Tags: